Prospective assessment of emotional distress, cognitive function, and quality of life in patients with cancer treated with chemotherapy
Gregoris Iconomou,Vasiliki Mega,Angelos Koutras,Alexander V. Iconomou,Haralabos P. Kalofonos +4 more
Reads0
Chats0
TLDR
The current study sought to delineate prospectively the rates and clinical course of emotional distress, cognitive impairment, and quality of life in chemotherapy‐naive patients with cancer and to consider the determinants of global QOL.Abstract:
BACKGROUND
The current study sought to delineate prospectively the rates and clinical course of emotional distress, cognitive impairment, and quality of life (QOL) in chemotherapy-naive patients with cancer and to consider the determinants of global QOL.
METHODS
Patients who consented to participate were administered the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire, the Mini-Mental State Examination (MMSE), and the Hospital Anxiety and Depression Scale before and at the end of treatment (EOT).
RESULTS
Of the 102 patients initially assessed, 80 (78.4%) completed the study. Most aspects of QOL did not change considerably over time. At EOT, patients reported only significant increases in fatigue and significant decreases in sleep disturbance. Although no significant changes emerged in the rates of anxiety or depression throughout chemotherapy, nearly one-third of the patients experienced severe emotional distress at both points in time. In addition, the authors observed neither significant alteration in the cognitive performance over time nor reliable associations between scores on the MMSE and subjective cognitive function, emotional distress, or QOL. Finally, depression proved to be the leading predictor of global QOL at baseline and at EOT.
CONCLUSIONS
The results indicated that a significant proportion of Greek patients with cancer experienced intense anxiety and depression throughout chemotherapy and confirmed the importance of depression as a strong predictor of global QOL. Routine screening of emotional distress across all phases of cancer is mandatory because it will contribute to the identification of patients who are in need of pharmaceutical and/or psychologic intervention. Cancer 2004. © 2004 American Cancer Society.read more
Citations
More filters
Journal ArticleDOI
Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases.
Rein Willemze,Patty M. Jansen,Lorenzo Cerroni,Emilio Berti,Marco Santucci,Chalid Assaf,Marijke R. Canninga-van Dijk,Agnes Carlotti,M.L. Geerts,Sonja Hahtola,Michael Hummel,Leila Jeskanen,Werner Kempf,Cesare Massone,Pablo L. Ortiz-Romero,Marco Paulli,Tony Petrella,Annamari Ranki,José L. Rodriguez Peralto,Alistair Robson,Nancy J. Senff,Maarten H. Vermeer,Janine Wechsler,Sean Whittaker,Chris J.L.M. Meijer +24 more
TL;DR: SPTL-ABs without associated HPS have an excellent prognosis, and multiagent chemotherapy as first choice of treatment should be questioned, while SPTL-GDs often showed (epi)dermal involvement and/or ulceration, a CD4-, CD8-, CD56+/-, betaF1- T-cell phenotype, and poor prognosis (5-year OS: 11%), irrespective of the presence of HPS or type of treatment.
Journal ArticleDOI
Objective and subjective cognitive impairment following chemotherapy for cancer: A systematic review
TL;DR: Only eight of 24 included studies found a significant relationship between objective and subjective measures of cognitive performance, and further research is required to explore whether objective measures of everyday functioning better predict the impact of chemotherapy related cognitive impairment on daily functioning.
Journal ArticleDOI
Evaluation of Cognitive Function Associated With Chemotherapy: A Review of Published Studies and Recommendations for Future Research
TL;DR: There is no consistency in defining cognitive impairment, in the NP batteries used, or in statistical methods in studies of cognitive function of cancer patients, and guidelines are suggested to define criteria for cognitive impairment.
Journal ArticleDOI
Cognitive function after chemotherapy in adults with solid tumours
Janette L. Vardy,Ian F. Tannock +1 more
TL;DR: Most evidence suggests an association with chemotherapy although other factors associated with the diagnosis and treatment of cancer may contribute.
Journal ArticleDOI
Anxiety and depression in cancer patients compared with the general population
Andreas Hinz,O. Krauss,Johann Hauss,Michael Höckel,Rolf-Dieter Kortmann,Jens-Uwe Stolzenburg,Reinhold Schwarz +6 more
TL;DR: The results show that large sample sizes are necessary to evaluate the psychological situation of cancer patients, and that age and gender differences must be taken into account when several samples are compared.
References
More filters
Journal ArticleDOI
“Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician
Marshal F. Folstein,Marshal F. Folstein,Susan E B Folstein,Susan E B Folstein,Paul R. McHugh,Paul R. McHugh +5 more
TL;DR: A simplified, scored form of the cognitive mental status examination, the “Mini-Mental State” (MMS) which includes eleven questions, requires only 5-10 min to administer, and is therefore practical to use serially and routinely.
A practical method for grading the cognitive state of patients for the clinician
TL;DR: The Mini-Mental State (MMS) as mentioned in this paper is a simplified version of the standard WAIS with eleven questions and requires only 5-10 min to administer, and is therefore practical to use serially and routinely.
Journal ArticleDOI
The Hospital Anxiety and Depression Scale.
A. S. Zigmond,R. P. Snaith +1 more
TL;DR: It is suggested that the introduction of the scales into general hospital practice would facilitate the large task of detection and management of emotional disorder in patients under investigation and treatment in medical and surgical departments.
Journal ArticleDOI
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Neil K. Aaronson,Sam H Ahmedzai,Bengt Bergman,Monika Bullinger,Ann Cull,Nicole Duez,Antonio Filiberti,Henning Flechtner,Stewart B. Fleishman,Johanna C. J. M. de Haes,Stein Kaasa,M. Klee,David Osoba,Darius Razavi,Peter B. Rofe,Simon Schraub,Kommer C. A. Sneeuw,Marianne Sullivan,Fumikazu Takeda +18 more
TL;DR: The reliability and validity of the EORTC QLQ-C30 questionnaire were highly consistent across the three language-cultural groups studied: patients from English-speaking countries, Northern Europe, and Southern Europe.
Journal ArticleDOI
Impairment of Cognitive Function in Women Receiving Adjuvant Treatment for High-Risk Breast Cancer: High-Dose Versus Standard-Dose Chemotherapy
F.S.A.M. van Dam,Sanne B. Schagen,Martin J. Muller,Willem Boogerd,E. van der Wall,M.E. Droogleever Fortuyn,Sjoerd Rodenhuis +6 more
TL;DR: High-dose chemotherapy appears to impair cognitive functioning more than standard- dose chemotherapy, and central nervous system toxicity may be a dose-limiting factor in high-dose cancer treatment regimens.
Related Papers (5)
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Neil K. Aaronson,Sam H Ahmedzai,Bengt Bergman,Monika Bullinger,Ann Cull,Nicole Duez,Antonio Filiberti,Henning Flechtner,Stewart B. Fleishman,Johanna C. J. M. de Haes,Stein Kaasa,M. Klee,David Osoba,Darius Razavi,Peter B. Rofe,Simon Schraub,Kommer C. A. Sneeuw,Marianne Sullivan,Fumikazu Takeda +18 more